Vontobel Holding Ltd. Atea Pharmaceuticals, Inc. Transaction History

Vontobel Holding Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jun 03, 2024	BUY	$3.0 - $3.79 $296,772 - $374,921	98,924 Added 19.72%	600,461 $1.8 Million
Q3 2023 Oct 10, 2023	BUY	$3.0 - $3.79 $296,772 - $374,921	98,924 Added 19.72%	600,461 $1.8 Million
Q2 2023 Jun 03, 2024	BUY	$3.21 - $5.06 $387,405 - $610,676	120,687 Added 31.69%	501,537 $1.88 Million
Q2 2023 Jul 24, 2023	BUY	$3.21 - $5.06 $387,405 - $610,676	120,687 Added 31.69%	501,537 $1.88 Million
Q1 2023 Jun 03, 2024	BUY	$3.0 - $4.97 $1.14 Million - $1.89 Million	380,850 New	380,850 $1.28 Million
Q1 2023 Apr 12, 2023	BUY	$3.0 - $4.97 $298,341 - $494,251	99,447 Added 35.34%	380,850 $1.28 Million
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $1.22 Million - $1.74 Million	281,403 New	281,403 $1.35 Million
Q3 2021 Oct 29, 2021	SELL	$21.33 - $35.06 $261,207 - $429,344	-12,246 Reduced 52.51%	11,076 $388,000
Q2 2021 Aug 06, 2021	BUY	$19.22 - $59.08 $448,248 - $1.38 Million	23,322 New	23,322 $501,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $272M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.